 First results of study AML-BFM 98 have shown that the patients of the standard risk SR group did not benefit from an additional, second induction HAM. On this account we did not reintroduce this second induction course in the present study AML-BFM 2004. However, SR patients will take part in the randomisation of initial therapy with a general view to achieving higher effectiveness. 